NX-1207 Trial – Adding Minimal Treatment to Active Surveillance

Question Of The Week:

For patients on active surveillance, is there a

new clinical trial you think is interesting?

 Dr. Barken discusses the new trend of adding minimal

 treatment to the active surveillance program.

The related clinical trail:

Two-Dose Level Evaluation of NX-1207 for the

Treatment of Low Risk, Localized (T1c) Prostate Cancer.

ClinicalTrials.gov  Identifier NCT01620515

Ask Dr Barken Call In Show on Tuesday, July 31st at 6pm Pacific

Dial 1-877-727-3301 to hear the program.

This entry was posted in Active Surveillance, Clinical Trials, Treatments for Prostate Cancer and tagged . Bookmark the permalink.